Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.

ABSTRACT:

Introduction

The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in combination with anti-vascular endothelial growth factor receptor (VEGFR) agents have shown improved survival outcomes in recent studies. However, its efficacy related to survival outcomes as a first- or second-line agent and based on generations remains to be explored. This study estimated the survival outcomes of EGFR-TKIs plus anti-VEGFR in combination in defined populations of advanced non-small cell lung cancer (NSCLC) patients overall, as a first- or second line of treatment, with different generations of EGFR-TKIs and EGFR-TKIs plus bevacizumab combination as a subgroup.

Methods

A literature search was conducted using PubMed, SCOPUS, Cochrane Library, and ClinicalTrials.gov dat

SUBMITTER: Sakharkar P 

PROVIDER: S-EPMC10969009 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature